MA28212A1 - 2-carbonylamino-6-piperidinaminopyridines substitues et 1-carbonylamino-3-piperidinaminobenzenes substitues utilises en tant qu'agonistes de 5-ht1f - Google Patents
2-carbonylamino-6-piperidinaminopyridines substitues et 1-carbonylamino-3-piperidinaminobenzenes substitues utilises en tant qu'agonistes de 5-ht1fInfo
- Publication number
- MA28212A1 MA28212A1 MA28928A MA28928A MA28212A1 MA 28212 A1 MA28212 A1 MA 28212A1 MA 28928 A MA28928 A MA 28928A MA 28928 A MA28928 A MA 28928A MA 28212 A1 MA28212 A1 MA 28212A1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- hydrogen
- alkyl
- carbonylamino
- piperidinaminopyridines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule ou un sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, où X représente -C(R3c)= ou ~N=; R1 représente alkyle en C2-C6, alkyle en C2-C6 substitué, cycloalkyle en C3-C7, cycloalkyle en C3-C7 substitué, phényle, phényle substitué, hétérocycle ou hétérocycle substitué; R2 représente hydrogène, n-alkyle en C1-C3, (cycloalkyle en C3-C6)-(alkyle en d- C3) ou un groupe de formule II à condition que lorsque R1 représente alkyle en C2-C6 ou alkyle en C2-C6 substitué, R2 représente hydrogène ou méthyle; R3a R3b et |orSqUe x représente -C(R3c)=, R3c, représentent, indépendamment l'un de l'autre hydrogène, fluoro ou méthyle, à condition que pas plus d'un radical parmi R3a, R3b et R3c puisse être différent d'hydrogène; R4 représente hydrogène ou alkyle en C1-C3; R5 représente hydrogène, alkyle en C1-C3 ou cycloalkylcarbonyle en C3-C6, à condition que lorsque R3a est différent d'hydrogène, R5 représente hydrogène; R6 représente hydrogène ou alkyle en C-i-Ce; et n représente un entier de 1 à 6 compris. Les composés de la présente invention sont utiles pour activer les récepteurs 5- HTIF, inhiber l'extravasation de protéines neuronales et pour le traitement ou la prévention de la migraine chez un mammifère.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50278003P | 2003-09-12 | 2003-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28212A1 true MA28212A1 (fr) | 2006-10-02 |
Family
ID=34434850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28928A MA28212A1 (fr) | 2003-09-12 | 2006-04-10 | 2-carbonylamino-6-piperidinaminopyridines substitues et 1-carbonylamino-3-piperidinaminobenzenes substitues utilises en tant qu'agonistes de 5-ht1f |
Country Status (30)
Country | Link |
---|---|
US (3) | US7291632B2 (fr) |
EP (1) | EP1663971B1 (fr) |
JP (1) | JP4700614B2 (fr) |
KR (1) | KR100777875B1 (fr) |
CN (1) | CN1849307B (fr) |
AR (1) | AR045619A1 (fr) |
AT (1) | ATE538093T1 (fr) |
AU (1) | AU2004280320B2 (fr) |
BR (1) | BRPI0414241A (fr) |
CA (1) | CA2537936C (fr) |
CR (1) | CR8275A (fr) |
CY (1) | CY1112475T1 (fr) |
DK (1) | DK1663971T3 (fr) |
EA (1) | EA011274B1 (fr) |
EC (1) | ECSP066415A (fr) |
ES (1) | ES2379665T3 (fr) |
IL (1) | IL173521A (fr) |
MA (1) | MA28212A1 (fr) |
MX (1) | MXPA06002767A (fr) |
MY (1) | MY144623A (fr) |
NO (1) | NO20061584L (fr) |
NZ (1) | NZ545049A (fr) |
PE (1) | PE20050350A1 (fr) |
PL (1) | PL1663971T3 (fr) |
PT (1) | PT1663971E (fr) |
SI (1) | SI1663971T1 (fr) |
TW (1) | TWI340740B (fr) |
UA (1) | UA82711C2 (fr) |
WO (1) | WO2005035499A1 (fr) |
ZA (1) | ZA200602072B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
UA82711C2 (en) * | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
DE102005055892A1 (de) * | 2005-11-22 | 2007-05-24 | Henkel Kgaa | Neue Kupplerkomponenten |
NZ596161A (en) * | 2009-04-02 | 2013-11-29 | Colucid Pharmaceuticals Inc | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
EP2476677A1 (fr) * | 2009-09-08 | 2012-07-18 | Kyorin Pharmaceutical Co., Ltd. | Procédé de production de dérivés de l'acide 4-(5-méthylpyridine-2-ylamino)pipéridine-1-carboxylique |
CA2795062A1 (fr) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions et methodes de synthese d'agonistes des recepteurs 5-ht1f derives de la pyridinoylpiperidine |
EP3027590A1 (fr) * | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hétéro)arylamides et sulfonamides, procédés permettant leur préparation et utilisations thérapeutiques de ceux-ci |
CN109596521A (zh) * | 2018-02-11 | 2019-04-09 | 中国科学院海洋研究所 | 磷钼蓝分光光度法中还原剂的保存方法 |
CN110437205B (zh) * | 2018-08-24 | 2022-07-08 | 广东东阳光药业有限公司 | 吡啶烯基哌啶衍生物及其用途 |
AR119319A1 (es) | 2019-07-09 | 2021-12-09 | Lilly Co Eli | Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida |
CN111004214B (zh) * | 2019-11-22 | 2021-06-08 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
WO2021097781A1 (fr) * | 2019-11-22 | 2021-05-27 | 广东东阳光药业有限公司 | Dérivé de pyridine méthylène pipéridine et son utilisation |
CN110845402B (zh) * | 2019-11-22 | 2023-05-09 | 广东东阳光药业有限公司 | 吡啶亚甲基哌嗪衍生物及其用途 |
CN113045540B (zh) * | 2019-12-27 | 2024-02-13 | 上海天慈国际药业有限公司 | 一种拉司米地坦的制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356904A (en) * | 1992-10-07 | 1994-10-18 | Merck & Co., Inc. | Carbostyril oxytocin receptor antagonists |
DE4320484A1 (de) * | 1993-06-21 | 1994-12-22 | Dornier Gmbh | Steuerbares Supraleiter-Bauelement |
US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
KR19980703048A (ko) | 1995-03-20 | 1998-09-05 | 피터쥐.스트링거 | 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1h-인돌: 신규한 5-ht1f 아고니스트 |
CA2234166A1 (fr) | 1995-10-10 | 1997-04-17 | Patric James Hahn | Les n-¬2-substitue-3-(2-aminoethyl)-1h-indol-5-yl| - amides: de nouveaux agonistes 5-ht1f |
US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
JP2000516957A (ja) | 1996-08-28 | 2000-12-19 | イーライ・リリー・アンド・カンパニー | 置換されている1,2,3,4―テトラヒドロ―2―ジベンゾフランアミン類および2―アミノシクロヘプタ[b]ベンゾフラン類 |
AU4652697A (en) | 1996-10-08 | 1998-05-05 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
EP0875513A1 (fr) | 1997-04-14 | 1998-11-04 | Eli Lilly And Company | Composés hétéroaromatiques substitués agonistes du récepteur 5-HT1F |
ID23053A (id) | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
US5905084A (en) | 1997-11-14 | 1999-05-18 | Eli Lilly And Company | 5-HTIF -agonists effective in treating migraine |
WO2000000490A2 (fr) | 1998-06-26 | 2000-01-06 | Eli Lilly And Company | Agonistes de 5-ht¿1f? |
ES2209462T3 (es) | 1998-06-30 | 2004-06-16 | Eli Lilly And Company | Agonistas de 5-ht1f. |
AU1937300A (en) | 1998-12-11 | 2000-06-26 | Eli Lilly And Company | Indole derivatives and their use as 5-HT1F agonists |
EP1153013B1 (fr) * | 1999-02-10 | 2007-10-31 | Eli Lilly And Company | Agonistes 5-ht1f |
ES2214256T3 (es) | 1999-02-26 | 2004-09-16 | Eli Lilly And Company | Furo(3,2-b)piridinas como agonistas de 5-ht1f. |
AU2001241128A1 (en) * | 2000-03-14 | 2001-09-24 | Fujisawa Pharmaceutical Co. Ltd. | Novel amide compounds |
TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
BRPI0409211A (pt) * | 2003-04-18 | 2006-03-28 | Lilly Co Eli | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto |
UA82711C2 (en) * | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
-
2004
- 2004-03-09 UA UAA200602613A patent/UA82711C2/uk unknown
- 2004-08-12 TW TW093124248A patent/TWI340740B/zh not_active IP Right Cessation
- 2004-09-03 AU AU2004280320A patent/AU2004280320B2/en not_active Ceased
- 2004-09-03 MX MXPA06002767A patent/MXPA06002767A/es active IP Right Grant
- 2004-09-03 WO PCT/US2004/025607 patent/WO2005035499A1/fr active Application Filing
- 2004-09-03 SI SI200431842T patent/SI1663971T1/sl unknown
- 2004-09-03 AT AT04780442T patent/ATE538093T1/de active
- 2004-09-03 ES ES04780442T patent/ES2379665T3/es active Active
- 2004-09-03 EP EP04780442A patent/EP1663971B1/fr active Active
- 2004-09-03 KR KR1020067004982A patent/KR100777875B1/ko not_active IP Right Cessation
- 2004-09-03 DK DK04780442.2T patent/DK1663971T3/da active
- 2004-09-03 JP JP2006526084A patent/JP4700614B2/ja not_active Expired - Fee Related
- 2004-09-03 NZ NZ545049A patent/NZ545049A/en not_active IP Right Cessation
- 2004-09-03 US US10/569,109 patent/US7291632B2/en not_active Expired - Fee Related
- 2004-09-03 CN CN2004800264004A patent/CN1849307B/zh not_active Expired - Fee Related
- 2004-09-03 EA EA200600570A patent/EA011274B1/ru not_active IP Right Cessation
- 2004-09-03 PL PL04780442T patent/PL1663971T3/pl unknown
- 2004-09-03 CA CA2537936A patent/CA2537936C/fr not_active Expired - Fee Related
- 2004-09-03 BR BRPI0414241-1A patent/BRPI0414241A/pt not_active IP Right Cessation
- 2004-09-03 PT PT04780442T patent/PT1663971E/pt unknown
- 2004-09-08 PE PE2004000870A patent/PE20050350A1/es not_active Application Discontinuation
- 2004-09-09 MY MYPI20043665A patent/MY144623A/en unknown
- 2004-09-09 AR ARP040103232A patent/AR045619A1/es not_active Application Discontinuation
-
2006
- 2006-02-02 IL IL173521A patent/IL173521A/en not_active IP Right Cessation
- 2006-03-03 CR CR8275A patent/CR8275A/es unknown
- 2006-03-07 EC EC2006006415A patent/ECSP066415A/es unknown
- 2006-03-10 ZA ZA200602072A patent/ZA200602072B/en unknown
- 2006-04-07 NO NO20061584A patent/NO20061584L/no not_active Application Discontinuation
- 2006-04-10 MA MA28928A patent/MA28212A1/fr unknown
-
2007
- 2007-06-04 US US11/810,388 patent/US7803813B2/en not_active Expired - Fee Related
-
2010
- 2010-09-28 US US12/892,433 patent/US20110034511A1/en not_active Abandoned
-
2012
- 2012-03-12 CY CY20121100254T patent/CY1112475T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28212A1 (fr) | 2-carbonylamino-6-piperidinaminopyridines substitues et 1-carbonylamino-3-piperidinaminobenzenes substitues utilises en tant qu'agonistes de 5-ht1f | |
MA28438B1 (fr) | Derives azabicyclo (3.1.0) hexane utiles comme modulateurs des recepteurs d3 de la dopamine | |
MY134666A (en) | Pyridinoylpiperidines as 5-ht1f agonists | |
DE122004000039I2 (de) | Gaba und L-Glutaminsa}re analoga zur Behandlung der Epilepsie | |
MA30355B1 (fr) | Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3 | |
HRP20020175B1 (en) | N-heterocyclikc derivatives as nos inhibitors | |
MA30428B1 (fr) | Derives de dihydropyrazolopyrimidinones | |
CA2421114A1 (fr) | Derives 5-asa ayant une activite anti-inflammatoire et antibiotique, procedes de traitement de maladies a l'aide de ces derniers | |
MA32456B1 (fr) | Dérivé hétérocyclique contenant du soufre ayant une activité inhibant la b-sécrétase | |
WO2005012269A8 (fr) | Nouveau compose azole | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
TNSN05224A1 (fr) | Derives azabicycliques a substituants pyridyloxymethyle et benzisoxazole | |
MX9707531A (es) | Nuevos compuestos heterociclicos. | |
DE3876813T4 (de) | 3(2H)Pyridazinon, Verfahren zu dessen Herstellung und dieses enthaltendes Mittel gegen SRS-A. | |
KR880001680A (ko) | 1H, 3H-피롤[1,2-c]티아졸 유도체, 그의 제조 및 이들을 포함하는 제약학상의 조성물 | |
ES2145067T3 (es) | Composiciones farmaceuticas a base de analogos de argatroban. | |
AR034153A1 (es) | Compuesto quinolinahidrazona, el uso de un compuesto quinolinahidrazona para la manufactura de un agente antioxidante y de un agente para marcar o inhibir quimicamente la agregacion de fibrillas amiloides y permitir su asociacion, metodo para tenir fibrillas amiloides, un metodo para detectar dichos | |
AU681021B2 (en) | Indole derivative and medicine containing the same | |
KR950018037A (ko) | 시알산 유도체 | |
WO2004054565A8 (fr) | Pregabalin et derives de pregabalin pour le traitement de la fibromyalgie et d'autres troubles connexes | |
KR890701584A (ko) | 20, 21-디노르에비나메닌의 신규 치환 유도체, 그의 제조 방법 및 이 방법으로 얻는 신규 중간체, 약제로서의 그의 용도 및 그를 함유하는 제약 조성물 | |
SE0102289D0 (sv) | New use of compound | |
ATE370116T1 (de) | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten | |
WO2005002524A3 (fr) | Composes, compositions et utilisations therapeutiques de composes de type oleoylethanolamide et de modulateurs des ppar$g(a) | |
HUP0204278A2 (hu) | Nem peptid szubsztituált benzotiazepinszármazékok, mint vazopresszin antagonisták, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |